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Abstract
 
We have hypothesized that T cell cytokines participate in
the pathogenesis of graft arterial disease (GAD). This study
tested the consequences of IFN-
 
g
 
 deficiency on arterial and
parenchymal pathology in murine cardiac allografts. Hearts
from C-H-2
 
bm12
 
KhEg (bm12, H-2
 
bm12
 
) were transplanted
into C57/B6 (B6, H-2
 
b
 
), wild-type, or B6 IFN-
 
g
 
–deficient
(GKO) recipients after immunosuppression by treatment
with anti-CD4 and anti-CD8 mAbs. In wild-type recipients,
myocardial rejection peaked at 4 wk, (grade 2.1
 
6
 
0.3 out of
4, mean
 
6
 
SEM, 
 
n 
 
5
 
 9), and by 8–12 wk evolved coronary
arteriopathy. At 12 wk, the GAD score was 1.4
 
6
 
0.3, and the
parenchymal rejection grade was 1.2
 
6
 
0.3 (
 
n 
 
5
 
 8). In GKO
recipients of bm12 allografts, myocardial rejection persisted
at 12 wk (grade 2.5
 
6
 
0.3, 
 
n 
 
5
 
 6), but no GAD developed
(score: 0.0
 
6
 
0.0, 
 
n 
 
5
 
 6, 
 
P 
 
,
 
 0.01 vs. wild-type). Mice treated
with anti–IFN-
 
g
 
 mAbs showed similar results. Isografts
generally showed no arterial changes. In wild-type recipi-
ents, arterial and parenchymal cells showed increased MHC
class II molecules, intercellular adhesion molecule-1, and
vascular cell adhesion molecule-1 compared to normal or
isografted hearts. The allografts in GKO recipients showed
attenuated expression of these molecules (
 
n 
 
5
 
 6). Thus, de-
velopment of GAD, but not parenchymal rejection, requires
IFN-
 
g
 
. Reduced expression of MHC antigens and leukocyte
adhesion molecules may contribute to the lack of coronary
arteriopathy in hearts allografted into GKO mice. (
 
J. Clin.
Invest. 
 
1997. 100:550–557.)
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Introduction
 
Graft coronary arteriosclerosis currently constitutes the single
major limitation to long-term survival of cardiac allograft re-
cipients (1, 2). Concentric intimal thickening composed of vari-
able numbers of T cells, macrophages, and smooth muscle cells
beneath MHC class II bearing endothelium characterizes the
hallmark lesion of transplant arteriosclerosis (3, 4). Although
the precise molecular and cellular events that produce this ar-
teriopathy remain conjectural, they presumably involve multi-
ple factors. For example, immunological differences between
host and donor tissues (with resultant cellular and/or humoral
immunity) probably contribute to the pathogenesis, although
ischemic, infectious, and other etiologies have also been impli-
cated (5). We have hypothesized that graft coronary arterio-
sclerosis results in part from a persistent delayed-type hyper-
sensitivity response mediated by helper T lymphocytes activated
by encountering allogeneic class II MHC antigens (6). Endo-
thelial cells can stimulate such an allogeneic lymphocyte re-
sponse in vitro (6). T cells that encounter endothelial cells
bearing the foreign MHC class II molecules release cytokines
that can in turn modulate endothelial cell expression of MHC
antigens as well as macrophage activation. Activated T cells
hence orchestrate an elaborate cytokine cascade that may reg-
ulate the growth, migration, and extracellular matrix metabo-
lism of vascular smooth muscle cells, promoting the develop-
ment of the fibroproliferative intimal lesions characteristic of
graft coronary arteriosclerosis. IFN-
 
g
 
, a cytokine produced by
certain T cell subsets, would presumably occupy a proximal
position in this sequence by directly activating macrophages,
and by enhancing the expression of MHC products, other com-
ponents of the antigen presentation pathway, and adhesion
molecules (7–10). The present study tested the hypothesis that
IFN-
 
g
 
 contributes to the development of graft arterial disease
(GAD)
 
1
 
 in vascularized cardiac allografts, using mice with an
 
IFN-
 
g
 
 deficiency due either to targeted disruption of the 
 
IFN-
 
g
 
gene, or treatment with neutralizing antibody.
 
Methods
 
Animals.
 
Inbred mice of several strains were used. C-H-2
 
bm12
 
KhEg
(bm12, H-2
 
bm12
 
) were used as allograft donors. C57/BL6 (B6, H-2
 
b
 
)
and B6 IFN-
 
g
 
 knockout mouse (B6GKO, H-2
 
b
 
) were used as recipi-
ents. B6 to B6 isografts were used as controls. The original GKO
mice were generated by disrupting the 
 
IFN-
 
g
 
 gene, inserting a neo-
mycin-resistance gene (
 
neo
 
9
 
), and replacing one copy of the wild-type
gene in embryonic stem cells by homologous recombination. These
stem cells were used to construct mice heterozygous for the disrupted
gene; these mice were interbred, and the progeny were selected for
homozygosity (11). Heterozygous B6 and B6 mice with intact wild-
type 
 
IFN-
 
g
 
 genes were provided by Dr. Tim Stewart (Genentech Inc.,
South San Francisco, CA). The backcross mice were genotyped by
PCR amplification of tail DNA using two sets of primers: 482, 5
 
9
 
 gamma
AGAAGTAAGTGGAAGGGCCCAGAGG 3
 
9
 
; 484, 3
 
9
 
 gamma 5
 
9
 
AGGGAAACTGGGAGAGGAGAAATAT 3
 
9
 
; 725, 5
 
9
 
 neo TCAG-
CGCAGGGGCGCCCCGTTCTTT 3
 
9
 
; 727, 3
 
9
 
 neo 5
 
9
 
ATCGACA-
AGACCGGCTTCCATCCGA 3
 
9
 
. The first set amplifies a band of
220 bp on the intact 
 
IFN-
 
g
 
 gene, and the second set amplifies a band
of 375 bp on the region of the targeted mutation (neo
 
9
 
). The PCR was
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1. 
 
Abbreviations used in this paper:
 
 ECM, extracellular matrix; GAD,
graft arterial disease; GKO, IFN-
 
g
 
 knockout; ICAM-1, intercellular
adhesion molecule-1; VCAM-1, vascular cell adhesion molecule-1.
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run for 40 cycles (thermocycler; Perkin Elmer Corp., Norwalk, CT)
using 
 
Taq
 
 DNA polymerase (BRL, Burlington, Ontario, Canada) at
55
 
8
 
C annealing temperature. The PCR products were run on an
ethidium bromide gel; the GKO homozygous mice show a single
(neo
 
9
 
) band, the wild-type mice show a single IFN-
 
g
 
 band, and the
heterozygotes showed both bands. The heterozygotes were inter-
crossed, and the homozygous GKO mice were identified by tail DNA
testing. Homozygosity of the offspring was confirmed by further tail
testing, and by testing each mouse for IFN-
 
g
 
 mRNA expression by
reverse transcriptase PCR on spleen RNA at the time of experimen-
tal use. All GKO mice used were confirmed homozygotes, and were
from the eighth generation (or greater) backcross into the B6 paren-
tal strain. B6 with wild-type 
 
IFN-
 
g
 
 genes and bm12 mice aged 8–12
wk were obtained from Taconic Farms, Inc. (Germantown, NY) and
The Jackson Laboratory (Bar Harbor, ME). The mice were main-
tained in the Harvard Medical School animal facilities on acidified
water. Sentinel animals surveyed serologically for viral pathogens
were negative in the room in which these mice were housed. All ex-
periments conformed to approved animal care protocols approved by
the institutional review group.
 
Heart transplantation and immunosuppression.
 
Heterotopic car-
diac transplantation was performed using a modification of the
method descried by Corry et al. (12). In brief, donors and recipients
were anesthetized with Metofan (Pittman-Moore, Mundelein, IL).
Donor hearts were perfused with chilled and heparinized saline via
the inferior vena cava, and were harvested after ligation of the vena
cava and pulmonary veins. The aorta and pulmonary artery of donor
hearts were anastomosed to the abdominal aorta and inferior vena
cava, respectively, of recipients using a microsurgical technique. Isch-
emic time was routinely 25 min, with a success rate of 
 
z 
 
90%. The vi-
ability of the cardiac allograft was assessed by daily abdominal palpa-
tion. The day of graft failure was defined as the day of cessation of
heartbeat.
In some experiments, transplants were performed without immu-
nosuppression. In the remainder, immunosuppression was provided
typically by a brief course of treatment with anti-CD4 (GK 1.5) and
anti-CD8 (2.43) mAbs, according to a previous report (13). These
were administered 6, 3, and 1 d before transplantation as intraperito-
neal injections of 0.2 ml of ascites fluid containing each mAb with no
subsequent treatment. Anti–IFN-
 
g
 
 mAb (H-22, Armenian hamster
IgG; a generous gift of Dr. Abul Abbas, Harvard Medical School,
Boston, MA) was also used in some experiments. This mAb (250 
 
m
 
g
per treatment) was administered intraperitoneally every 7 d after
transplantation according to a previously reported protocol (14).
Polyclonal hamster IgG (PharMingen, San Diego, CA) was given to
some recipients in the same amount, route, and schedule as a control
for anti–IFN-
 
g
 
.
 
Histologic techniques.
 
The grafts were explanted at 4-wk inter-
vals up to 12 wk. The grafts were sectioned transversely, frozen in
OCT compound (Ames Co., Division of Miles Laboratories, Elkhart,
IN) and stored at 
 
2
 
80
 
8
 
C, and/or were fixed in 10% buffered formalin
for morphological examination. 4-
 
m
 
m-thick frozen sections of heart
in OCT were fixed in acetone for 10 min. For immunohistology, fro-
zen sections were stained with rat monoclonal antibodies against
CD45, CD4, CD8, Mac-3, 
 
a
 
-actin, MHC class II, intercellular adhe-
sion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1
(VCAM-1) using standard techniques. The sections were stained us-
ing rabbit anti–rat IgG by the avidin–biotin complex method (15),
and were counterstained with hematoxylin. Paraffin sections were
stained with hematoxylin and eosin and the elastic fiber stain using
Weigert’s method.
 
Monoclonal antibodies.
 
2.43 (anti-CD4) and GK1.5 (anti-CD8)
antibodies for immunosuppression were prepared from hybridoma
clones (American Type Culture Collection, Germantown, MD) and
used as ascites preparations, or from comparable concentrations of
antibody prepared from serum-free supernatants in an artificial capil-
lary system (Cellmax; Celluco Inc., Rockville, MD); antibodies for
ICAM-1, VCAM-1, CD4, CD8, CD45, Mac-3, and MHC class II were
purchased from PharMingen; antibody to 
 
a
 
-actin (IA4) was from
Sigma Chemical Co. (St. Louis, MO).
 
Histological evaluation and statistical analysis.
 
Grafts were ana-
lyzed by standard hematoxylin and eosin and elastin stains, and the
severity of parenchymal rejection versus GAD was scored blindly by
three independent observers (H. Nagano, R.N. Mitchell, and S. Hase-
gawa). Scores uniformly fell within a range of one grade for all ob-
servers, and were averaged. Parenchymal rejection was graded using
a scale modified from the International Society for Heart and Lung
Transplantation (16) (0, no rejection; 1, mild interstitial or perivascu-
lar infiltrate without necrosis; 2, focal interstitial or perivascular infil-
trate with necrosis; 3, multifocal interstitial or perivascular infiltrate
with necrosis; and 4, widespread infiltrate with hemorrhage and/or
vasculitis), and a GAD score was calculated from the number and se-
verity of involved vessels (0, no or minimal [
 
,
 
 10%] vascular occlu-
sion; 1, 10–25% occlusion; 2, 25–50% occlusion; 3, 50–75% occlusion;
 
Table I. Parenchymal Rejection and GAD Score
 
4 wk 8 wk 12 wk
Strain Treatment PR GAD PR GAD PR GAD
 
bm12-B6 Anti-CD4 mAb
Anti-CD8 mAb
2.1
 
6
 
0.3
(
 
n
 
 
 
5
 
 9)
0.4
 
6
 
0.1 2.0
 
6
 
0.5
(
 
n
 
 
 
5
 
 9)
1.3
 
6
 
0.4 1.2
 
6
 
0.3
(
 
n
 
 
 
5
 
 8)
1.4
 
6
 
0.3
bm12-B6GKO Anti-CD4 mAb
Anti-CD8 mAb
2.0
 
6
 
0.5
(
 
n
 
 
 
5 
 
6)
0
 
6
 
0
 
‡
 
2.3
 
6
 
0.3
(
 
n
 
 
 
5
 
 6)
0.1
 
6
 
0.1* 3.2
 
6
 
0.2
(
 
n
 
 
 
5
 
 6)
0
 
6
 
0*
bm12-B6 Anti-CD4 mAb
Anti-CD8 mAb
Anti–IFN-
 
g
 
 mAb (H-22)
1.4
 
6
 
0.3
(
 
n
 
 
 
5
 
 4)
0.6
 
6
 
0.5
 
‡
 
bm12-B6 Anti-CD4 mAb
Anti-CD8 mAb
Hamster control IgG
2.8
 
6
 
0.2
(
 
n
 
 
 
5
 
 2)
2.6
 
6
 
0.2
B6-B6 Anti-CD4 mAb
Anti-CD8 mAb
0
 
6
 
0
(
 
n
 
 
 
5
 
 5)
0
 
6
 
0
 
‡
 
0
 
6
 
0
(
 
n
 
 
 
5
 
 3)
0
 
60* 060
(n 5 5)
0.160.1*
B6-B6 (2)0 6 00 6 0 ‡ 0 6 00 6 0* 0600 6 0*
(n 5 3) (n 5 3) (n 5 3)
PR, parenchymal rejection; *P , 0.01 vs. bm12-B6 with anti-CD4 and -CD8 mAb treatment; ‡P , 0.05 vs. bm12-B6 with anti-CD4 and -CD8 mAb
treatment.552 Nagano et al.
4, 75–100% occlusion). The cellularity versus extracellular matrix
(ECM) content of GAD was assessed blindly by one observer (R.N.
Mitchell) using scanned photographic images of all GAD lesions
(366–100) and image analysis (5.2 software; Optimas Corp., Bothell,
WA). Thresholds for nuclear versus nonnuclear staining were set us-
ing two-pixel averages; intimal lesions delimited by the internal elas-
tic lamina were scored independently for percentage of area encom-
passed by nuclei (as an approximate measure of cellularity), versus
nonnuclear staining (as an approximation of ECM). Areas of nuclear
plus nonnuclear staining were normalized to 1. All results are ex-
pressed as the mean6SEM. Statistical analysis was performed by
one-way ANOVA. P , 0.05 was considered statistically significant.
Results
All of the bm12 allografts immunosuppressed by treatment
with preoperative anti-CD4 and anti-CD8 mAbs continued to
beat until harvested (up to 12 wk) in both the wild-type and
GKO recipients, although all exhibited substantial myocardial
rejection. In the wild-type recipients, rejection was maximal at
the earliest time point examined (4 wk), and diminished at
later times; the coronary arteriopathy progressively increased
with time (Figs. 1 and 2, Table I). When present at 4 wk, the
arterial lesions in the transplanted coronary arteries predomi-
nantly consisted of accumulations of CD451 mononuclear
cells. At later time points, the lesions became markedly less
cellular, with a relative increase in ECM. These later lesions
consisted mainly of smooth muscle cells and MAC-31 mac-
rophages, and morphologically resembled typical human
transplantation–associated arteriosclerosis. Some of these fi-
broproliferative lesions resulted in virtually complete occlu-
sion of the coronary arteries. Many cells in the lesions dis-
played increased expression of MHC class II, ICAM-1, and
VCAM-1 (see Fig. 4, Table II). Except for a single isograft
with extensive ischemic injury, isografts showed neither myo-
cardial rejection nor arteriopathy with (n 5 13) or without
(n 5 9) anti-CD4 and anti-CD8 mAb pretreatment (Table I).
In comparison, and despite ongoing parenchymal rejection,
allografts in IFN-g–deficient mice developed little or no arteri-
opathy (Figs. 1 and 3, Table I). Even at time points up to 12
wk, hearts in the IFN-g–deficient recipients showed negligible
coronary arterial intimal thickening. In addition, the GKO re-
cipient allografts showed markedly attenuated expression of
VCAM-1 and ICAM-1 in arterial cells, and of MHC class II in
arterial cells and infiltrating leukocytes (Table II, Fig. 4).
Congenital absence of the immunostimulatory cytokine
IFN-g might conceivably alter the ontogeny of the immune re-
sponse in ways that could influence the development of arte-
rial pathology. Therefore, to verify that deficiency of IFN-g it-
self interrupts the development of graft vascular disease, we
administered a neutralizing antibody to IFN-g after trans-
plants into wild-type mice. As in the IFN-g–deficient animals,
hearts of bm12 allografts in B6 wild-type recipients treated
Figure 1. (A) Comparison between parenchymal rejection grade and the grade 
of GAD in bm12 allografts into C57/B6 recipient mice. Parenchymal rejection 
peaked at 4 wk after transplantation and subsequently diminished, while GAD 
increased progressively. (B) The composition of GAD lesions (cellularity and 
ECM) in the same series of animals as A. These were assessed by image analy-
sis of photographs of all GAD lesions with thresholds set for nuclear versus 
nonnuclear staining. The ordinate marks the percentage of intimal lesions oc-
cupied by nuclei as an approximation of cellularity, or by nonnuclear material, 
as an estimate of ECM. When present at 4 wk after transplantation, GAD con-
sisted predominantly of mononuclear inflammatory cells. At later time points, 
GAD showed progressively less cellularity with a relative increase in ECM. 
These later lesions show many characteristics typical of late-stage human graft 
arteriosclerosis. (C) Comparison between parenchymal rejection and GAD in 
bm12 allografts into B6 GKO recipient mice. There was moderate to severe in-
filtration of lymphocytes in the parenchyma, but few vascular changes ap-
peared for up to 12 wk after transplantation. (A) Parenchymal rejection, black 
bars; graft arterial disease, gray bars; (B) cellularity, black bars; ECM, gray 
bars; (C) parenchymal rejection, black bars; graft arterial disease, gray bars. 
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Figure 2. (A) A representative section of an allograft from bm12 to 
C57/B6, 4 wk after transplantation. The recipient was pretreated with 
anti-CD4 and anti-CD8 mAbs (elastin stain, 340). Note the focal 
mononuclear inflammatory cell infiltration in the parenchyma. Pa-
renchymal rejection grade: 3–4. GAD grade: 1; the cellularity is as-
sessed as 64.4% and the ECM as 35.6%. (B) A representative section 
of an allograft from bm12 to C57/B6, 8 wk after transplantation (elas-
tin stain, 350). Extensive infiltrate expanding the intima and compro-
mising the lumen. Parenchymal rejection grade: 3; GAD grade: 4; the 
cellularity is assessed as 54.8% and the ECM as 45.2%. (C) A repre-
sentative section of an allograft from bm12 to C57/B6, 12 wk after 
transplantation (elastin stain, 333). Marked fibrointimal expansion 
and luminal stenosis, morphologically resembling typical human graft 
arteriosclerosis. Parenchymal rejection grade: 2; GAD grade: 3; the 
cellularity is assessed as 31.8%, and the ECM as 68.2%.
Figure 3. (A) A representative section of an allograft from bm12 to 
B6 GKO, 4 wk after transplantation (elastin stain, 340). Although a 
multifocal mononuclear inflammatory cell infiltration persists in the 
parenchyma (parenchymal rejection grade: 3), the artery did not have 
intimal disease (GAD grade: 0). (B) A representative section of an 
allograft from bm12 to B6 GKO, 8 wk after transplantation (elastin 
stain, 340). There is no GAD (parenchymal rejection grade: 3–4; 
GAD grade: 0). (C) A representative section of an allograft from 
bm12 to B6 GKO, 12 wk after transplantation (elastin stain, 333). 
The coronary artery lacks intimal thickening (parenchymal rejection 
grade: 3; GAD grade: 0).
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with anti–IFN-g mAb showed little (one of four recipients) or
no (three of four recipients) arteriopathy (score: 0.660.5, n 5
4 at 8 wk). These anti–IFN-g antibody-treated mouse heart al-
lografts did, however, develop significant myocardial rejection
(grade: 1.460.3, n 5 4 at 8 wk) (Table I, Fig. 5). As in GKO re-
cipients, there was diminished MHC class II, ICAM-1, and
VCAM-1 expression in transplant recipients treated with anti–
IFN-g antibodies. In comparison, grafts in mice treated with
control nonspecific IgG showed typical rejection and GAD
(scores of 3–4) comparable to untreated bm12 to B6 allografts.
Discussion
This study used vascularized cardiac transplantation in mice to
probe the pathogenesis of the accelerated arteriosclerosis that
develops in allografted organs. In the MHC class II–disparate
donor–recipient combination studied here, coronary arterial
lesions develop that morphologically and immunopathologi-
cally resemble those seen in human transplantation arterio-
sclerosis (6, 17). Although it has not been possible to examine
histologically the sequence of events during the development
of GAD in human transplants, the mouse model clearly lends
itself to such an analysis. 4 wk after transplantation, arteries ex-
hibit a vasculitis characterized by perivascular cuffing and in-
traluminal accumulations of mononuclear leukocytes (CD451
cells). By 8 wk, cell-rich intimal lesions have formed. At the
12-wk time point, the intimal lesions contain smooth muscle
cells as well as leukocytes, and have accumulated considerable
ECM. At this stage, the luminal surface of the arteries displays
scant leukocytes, and perivascular leukocyte accumulation has
diminished. This sequence of events suggests that an initial
lymphocytic vasculitis precedes development of the fibropro-
liferative arteriosclerotic lesions of advanced allograft arteri-
opathy.
Except for a single heart (and in only 1 of over 100 vessels
examined in 22 hearts) with extensive ischemic injury, no
isografts in this study (with or without antibody pretreatment)
showed GAD. The development of GAD in hearts trans-
planted across MHC barriers, but not in isografts, and the limi-
tation of vascular lesions to the allografted vascular tree, sup-
ports an immune-mediated mechanism for the development of
graft vascular disease. Nevertheless, nonimmunological mech-
anisms, such as ischemia/reperfusion injury, may also contrib-
ute to chronic rejection (18).
We postulated in 1989 that IFN-g plays a central role in ini-
tiating a cytokine and growth factor cascade that leads to the
development of allograft arteriopathy (19). The availability of
GKO mice permitted us to test critically the contribution of
IFN-g to the development of transplantation arteriosclerosis in
this model. Previous studies have established that GKO mice
(a) develop normally and are healthy in the absence of patho-
gens, and (b) have impaired microbicidal function (11). Our
GKO cardiac transplantation recipients, housed in a virus-
antibody free facility, have shown no evidence of infection
either before or after cardiac transplantation. In the GKO re-
cipient mice, despite the substantial perivascular and paren-
chymal infiltration by mononuclear cells, no appreciable inti-
mal thickening developed. Administration of a neutralizing
antibody to IFN-g after heart allografting into wild-type mice
verified that absence of IFN-g rather than some developmental
anomaly in the immune response in genetically IFN-g–deficient
mice accounted for the attenuated arteriopathy. These results
agree with previous work using anti–IFN-g antibodies (20).
IFN-g regulates the proliferation and function of activated
T lymphocytes (21–23), and plays a pivotal role in rejection by
activating macrophages (24–26). In this study, T lymphocytes
and macrophages infiltrated the myocardium and coronary ar-
teries of allografts in the wild-type recipients. In contrast, IFN-
g–deficient recipients did not develop thickening of the arte-
rial intima, despite a T lymphocyte and macrophage infiltrate
in the parenchyma. IFN-g powerfully stimulates the increased
synthesis and cell surface expression of both class I and II
MHC antigens in vivo (27, 28), including bone marrow–
derived immunocompetent cells, as well as vessel wall cells
(19, 29–33).
Induction of local tissue injury by LPS in GKO mice re-
vealed an essential role for IFN-g in the induction of MHC
class I and II expression in arterial endothelium (34). Similarly,
in the present study, endothelial cells and smooth muscle cells
of grafts in GKO recipients displayed markedly diminished
MHC class II expression relative to wild-type recipients.
Endothelial cells increase their expression of surface adhe-
sion proteins, including VCAM-1 or ICAM-1, in response to
inflammatory cytokines (10, 35–39). In transplanted coronary
arteries, medial smooth muscle cells as well as endothelial cells
can express VCAM-1 (40). Vascular endothelia, in rejecting
mouse and rabbit cardiac allografts, express VCAM-1 (41, 42).
IFN-g may contribute to this process (35, 36, 38). This adhe-
sion molecule upregulation may be important, since treatment
with anti–VCAM-1 antibody induces long-term acceptance of
murine cardiac allografts (43). ICAM-1 (the receptor for the
leukocyte surface molecule LFA-1) may also contribute to
acute and/or chronic allograft rejection. Treatment with anti–
ICAM-1 and anti–LFA-1 mAbs, for example, inhibits acute
cardiac allograft rejection, and induces donor-specific alloge-
neic skin graft acceptance in mice (44). Coronary arterioscle-
rotic lesions in transplanted mouse hearts show abundant
ICAM-1, especially on the endothelial surface (40). Treatment
with mAbs to ICAM-1 and LFA-1 limited coronary arterio-
sclerosis in transplanted mouse hearts (45), although the de-
gree to which this finding results from diminished parenchy-
mal rejection is not apparent. In the present study, endothelial
and smooth muscle cells in wild-type recipients showed in-
creased VCAM-1 and ICAM-1 expression during develop-
Table II. Summary of Immunohistology (8 Weeks
After Transplantation)
bm12-B6 bm12-B6 GKO
Parenchyma Artery Parenchyma Artery
Mac-3 111 111 11 1
CD45 1 111 111 1
CD4 11 11 11 1
CD8 1162
MHC Class II 11 11 1 2
IFN-g 1 1 122
a -actin NA 11 NA 11
ICAM-1 111 11 1 1
VCAM-1 NA 11 NA 6
NA, not applicable; 2, not present; 6, weak or focal staining; 1–111,
progressively stronger and/or diffuse staining.Interferon-g Deficiency Prevents Coronary Arteriosclerosis 555
Figure 4. Immunohistochemical staining of representative sections from bm12 to B6 wild-type and bm12 to B6 GKO recipients, 8 wk after trans-
plantation. B6 wild-type recipient grafts displayed increased MHC class II (A, 350), ICAM-1 (C, 350), and VCAM-1 (E, 350). In contrast, B6 
GKO recipients showed low levels of MHC class II (B, 350), ICAM-1 (D, 350), and VCAM-1 (F, 350) expression.556 Nagano et al.
ment of intimal lesions, while IFN-g–deficient recipients
showed much lower levels of these adhesion molecules. The
finding of diminished MHC class II and adhesion molecule ex-
pression in GKO mice suggests mechanisms by which lack of
IFN-g may attenuate allograft arteriopathy.
The present study used an MHC class II disparate combi-
nation to examine the mechanism of development of graft vas-
cular disease. CD41 T cells interact preferentially with class II
MHC molecules, rendering this choice appropriate for study of
the effects of IFN-g, a strong inducer of this class of MHC mol-
ecules (46) as well as in activating macrophages. Indeed, in a
carotid interposition model, mice deficient in CD81 T cells or
natural killer cells develop significant allograft arterial lesions,
while mice deficient in CD41 T cells or macrophages show re-
duced intimal lesion formation (25). The possibility exists that
the abrogation of GAD is attributable to a diminished MHC
class II expression in a strain combination (bm12 to B6) where
the immune response depends on class II difference. Similar
results, however, were obtained in completely mismatched al-
lografts (BALB/c (H-2d) to B6; data not shown).
In terms of the contribution of IFN-g, our data show a clear
difference in the pathogenesis of GAD versus parenchymal re-
jection. Although IFN-g appears necessary for coronary inti-
mal thickening, non–IFN-g–dependent mechanisms suffice to
generate parenchymal rejection. Indeed, in addition to the per-
sistent diffuse mononuclear cell inflammatory infiltrate in the
parenchyma, nonimmunosuppressed GKO recipients demon-
strate accelerated cardiac allograft failure, indicating a more
aggressive rejection (our own observation and reference 47).
This mechanistic dichotomy illustrates why the term chronic
rejection may be imprecise in context of cardiac allografts.
Some transplantation pathologists use chronic rejection to re-
fer to the proliferative intimal lesion of GAD, however,
chronic rejection implies a mechanistic commonality with
acute rejection, which may not pertain as shown herein. More-
over, acute rejection refers to a myocardial rather than to a
vascular process. Because of this potential ambiguity, we advo-
cate avoiding the term chronic rejection altogether. We prefer
to use persistent myocardial rejection to describe the smolder-
ing or indolent parenchymal process seen at endomyocardial
biopsy, and graft arterial disease or graft vascular disease to
describe the vascular pathology.
Our results support the view that the development of GAD
results from a response of cells within the donor coronary ar-
teries to stimuli released during a chronic, localized form of
delayed-type hypersensitivity to alloantigens on graft-derived
vessel wall cells. In such a reaction, host helper T cells acti-
vated by encountering foreign histocompatibility antigens se-
crete IL-2, IFN-g, and TNF. The present data identify IFN-g
among these cytokines as an essential mediator of GAD. IFN-g
secreted by the T cells, activated by contact with foreign MHC,
might trigger the next wave of responses within the trans-
planted arteries, and stimulate expression of MHC class II,
VCAM-1, and ICAM-1 on the surface of vascular endothelial
cells, culminating in an accentuated local immune response.
IFN-g might also activate macrophages, with subsequent in-
creased production of other fibrogenic mediators including
IL-1, IL-6, PDGF, and TNF-a.
These data establish a critical role for IFN-g in the patho-
genesis of coronary arteriosclerosis in transplanted hearts, but
not in myocardial rejection. These data further indicate that
reduced expression of class II histocompatibility antigens and
leukocyte adhesion molecules may contribute to the mecha-
nism of attenuated coronary arteriopathy in hearts allografted
into IFN-g–deficient mice.
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Figure 5. (A) A representative section of an allograft from bm12 to 
B6 wild-type recipients treated weekly with anti–IFN-g mAb postop-
erative treatment, 8 wk after transplantation (elastin stain, 333). 
Note the substantial myocardial rejection and the virtual absence of 
GAD (parenchymal rejection grade: 3; GAD grade: 0). (B) A repre-
sentative section of an allograft from bm12 to B6 wild-type recipients 
treated with control hamster IgG postoperative treatment, 8 wk after 
transplantation (elastin stain, 333). Note the profound GAD with pa-
renchymal rejection (parenchymal rejection grade: 3; GAD grade: 3).Interferon-g Deficiency Prevents Coronary Arteriosclerosis 557
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